Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP lifted its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 274.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,181 shares of the company’s stock after acquiring an additional 81,519 shares during the period. Quantbot Technologies LP’s holdings in Amneal Pharmaceuticals were worth $925,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals by 0.6% during the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock worth $83,193,000 after purchasing an additional 85,846 shares during the period. Rubric Capital Management LP raised its position in shares of Amneal Pharmaceuticals by 12.4% in the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after buying an additional 1,179,830 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Amneal Pharmaceuticals by 17.6% in the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock valued at $27,205,000 after acquiring an additional 641,405 shares during the last quarter. Nantahala Capital Management LLC grew its position in Amneal Pharmaceuticals by 1.9% during the second quarter. Nantahala Capital Management LLC now owns 2,669,943 shares of the company’s stock valued at $16,954,000 after acquiring an additional 50,000 shares during the period. Finally, BlackBarn Capital Partners LP increased its stake in Amneal Pharmaceuticals by 41.5% during the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company’s stock worth $12,700,000 after acquiring an additional 586,703 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares in the company, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $8.27 on Monday. The company’s fifty day moving average price is $8.52 and its two-hundred day moving average price is $7.79. The firm has a market capitalization of $2.56 billion, a P/E ratio of -12.16 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 12 month low of $4.17 and a 12 month high of $9.48.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Barclays lifted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a research note on Friday, September 6th. Truist Financial upped their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd. Finally, Piper Sandler raised their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and an average price target of $10.00.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.